Verrica Pharmaceuticals Inc. (VRCA) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 6 Buy, 4 Hold.
The consensus price target is $17.00, representing an upside of 197.2% from the current price $5.72.
Analysts estimate Earnings Per Share (EPS) of $-14.46 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.48 vs est $-14.46 (beat +89.8%). 2025: actual $-1.68 vs est $-1.26 (missed -33.6%). Analyst accuracy: 0%.
VRCA Stock — 12-Month Price Forecast
$17.00
▲ +197.20% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Verrica Pharmaceuticals Inc., the price target is $17.00.
The average price target represents a +197.20% change from the last price of $5.72.
VRCA Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Verrica Pharmaceuticals Inc. in the past 3 months
EPS Estimates — VRCA
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.48
vs Est –$14.46
▲ 877.0% off
2025
Actual –$1.68
vs Est –$1.26
▼ 25.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — VRCA
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.008B
vs Est $0.008B
▼ 9.1% off
2025
Actual $0.036B
vs Est $0.035B
▲ 1.6% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
